1. Home
  2. Mandates
  3. Vinge has advised Oncopeptides in connection with entering into agreements regarding a loan facility of up to EUR 40 million from the EIB

Mandate Vinge has advised Oncopeptides in connection with entering into agreements regarding a loan facility of up to EUR 40 million from the EIB

October 16, 2020

The loan agreement with the EIB grants Oncopeptides access to an unsecured loan facility of up to EUR 40 million. The loan may be used to further support the clinical development of melflufen and the company’s transition from a R&D company into a fully integrated global biopharmaceutical company. In connection with the loan agreement, Oncopeptides has entered into a warrant agreement with the EIB, entitling the EIB to warrants in the company should the company draw on the loan facility.

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Louise Brorsson Salomon, Dain Hård Nevonen, Sofie Bjärtun, Linnéa Sellström and Viktor Lennartsson.

 

Summary of employment related news in Sweden as of January 2021

 Short-time work, a new pandemic law and pending changes to the Employment Protection Act. Here is the latest employment related news in Sweden.
January 19, 2021

Vinge in first place when the transaction year 2020 is summarized
January 07, 2021

Sanctions round-up

Not so long ago, sanctions were a rare occurrence which only involved obscure products and countries, and which were decided by the members of the United Nations Security Council. Today, the European Union and particularly the United States, impose sanctions and other trade restrictions with high frequency which have the potential to affect any type of transaction. Set forth below is a summary of some recent developments.
December 22, 2020